The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Dissenting Statement of Commissioners Maureen K. Ohlhausen and Joshua D. Wright - Federal Trade Commission v. Genesis Today, Inc., Pure Health LLC, and Lindsey Duncan
20150465: Interfor Corporation; Kamilche Company
20150426: Sanofi; Bayer AG
20150437: Johnson & Johnson; MacroGenics, Inc.
20150439: SCTG, LLC; SCANA Corporation
20150450: Farmers Mutual Hall Insurance Company of Iowa; Deere & Company
20150466: Cisco Systems, Inc.; Altiostar Networks, Inc.
20150471: Anthem, Inc.; Miguel B. Fernandez
80 FR 2934
Medtronic, Inc. and Covidien plc, In the Matter of
Global medical technology company Medtronic, Inc. agreed to divest the drug-coated balloon catheter business of Ireland-based medical products company Covidien plc, in order to settle FTC charges that its $42.9 billion acquisition of Covidien would likely be anticompetitive. Under the FTC’s proposed settlement, Medtronic will sell the drug-coated balloon catheter business to a Colorado-based medical device company, The Spectranetics Corporation. According to the FTC’s complaint, both Medtronic and Covidien are developing drug-coated balloon catheters to compete with C.R. Bard, Inc., which currently is the only company that supplies these products, used to treat peripheral artery disease, in the U.S. market. Medtronic and Covidien are the only companies with products in clinical trials in the Food and Drug Administration’s approval process, which makes it unlikely that other competitors could enter the market in time to counteract the effects of the merger.